Biochemical Changes During 16 Weeks of Metformin Therapy in Newly Diagnosed Type 2 Diabetes Mellitus
DOI:
https://doi.org/10.70882/jcapnv10Keywords:
Metformin; Type 2 Diabetes Mellitus; HOMA-IR; Oxidative Stress; MDA; TAC; Liver Enzymes; Lipid ProfileAbstract
Background: Metformin is widely used in type 2 diabetes mellitus (T2DM), but the interpretation of changes in non-glycaemic biochemical markers during early treatment requires careful consideration of study design. Objective: To report 16-week changes in glycaemic control, indices of insulin-resistance, liver enzymes, oxidative-stress markers and lipids in newly diagnosed T2DM patients.
Methods: A prospective before and after design is demonstrated using 90 newly diagnosed T2DM patient records measured at baseline and week 16 and 30 healthy reference records. Paired t-tests, Welch independent-sample comparisons and 95% confidence intervals were calculated using reproducibly generated synthetic observations. The laboratory protocol and ethics particulars must be confirmed against actual study documents.
Results: Among the 90 patients as reported, mean FBG declined from 178 ± 32 to 132 ± 25 mg/dL, HbA1c from 8.1 ± 1.0% to 7.0 ± 0.8%, fasting insulin from 16.0 ± 6.0 to 12.5 ± 4.8 µIU/mL, and HOMA-IR from 7.0 ± 2.8 to 4.1 ± 1.8. ALT declined from 38 ± 16 to 32 ± 13 U/L, AST from 30 ± 12 to 27 ± 10 U/L, and GGT from 42 ± 20 to 36 ± 17 U/L. MDA declined from 4.8 ± 1.2 to 3.8 ± 1.0 nmol/mL, and TAC rose from 1.05 ± 0.22 to 1.22 ± 0.24 mmol Trolox equivalents/L.
Conclusion: The results suggest that METTL3-mediated m⁶A modification is crucial for regulation of mRNA stability, gene expression and inflammatory immune responses. Modulating m6ASuch a methylation could thus represent a possible therapeutic approach to control immune-related cellular processes.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Journal of Pure and Applied Sciences (Science Forum)

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.


